For very high-risk patients, EBRT + BT is superior to surgery or EBRT only

A retrospective analysis of oncological outcomes among modern-era patients with a Gleason score of 9 or 10 demonstrates a clear advantage to a combination of external beam radiation therapy (EBRT) with a brachytherapy (BT) boost to the prostate and short–term androgen deprivation therapy (ADT). … READ MORE …

5-year outcomes after PBRT at a single, high-volume, PBRT center

We have previously reported on the very good, albeit unremarkable, outcomes of proton beam radiation therapy (PBRT) as administered at the University of Florida Jacksonville. … READ MORE …

Are MRI-targeted biopsies “better” than standard 12-core TRUS-guided biopsies?

We often see recommendations that MRI-guided biopsies may be more accurate that transrectal ultrasound (TRUS)-guided biopsies in the diagnosis of prostate cancer. A new systematic review has attempted to assess the current status of data supporting or refuting this recommendation. … READ MORE …

Short-term (perioperative) outcomes of RALP compared to open surgery in 2008-09

A new study available on line as a full-text article in European Urology has provided a retrospective analysis of the perioperative outcomes of men undergoing radical prostatectomy for localized prostate cancer in a 15-month period between October 2008 and December 2009 at 20 percent of the community hospitals in the USA (including public hospitals and academic medical centers). … READ MORE …

VHA cancer management quality study does NOT include prostate cancer

A new study in the Journal of Clinical Oncology has provided data regarding the survival of men of 65 years and older diagnosed with and treated for selected cancers within the Veterans Health Administration (VHA) system as compared to similar men treated under the fee-for-service Medicare system. This study has received a lot of media coverage. … READ MORE …

Watchful waiting vs. external beam radiation: 15-year data from a randomized trial

According to a report presented today at the annual meeting of the American Society for Radiation Oncology (ASTRO) in Miami Beach, Florida, men with localized prostate cancer who were treated 15 years ago with external beam radiation therapy had no significant survival benefit compared to men followed with watchful waiting. … READ MORE …

How much hypofractionated IMRT is too much for localized prostate cancer?

A report to be presented at the upcoming meeting of the American Society for Radiation Oncology (ASTRO) offers 5-year outcome data from a trial comparing conventional intensity-modulated radiation therapy (IMRT) to the more recently developed hypofractionated IMRT for men with localized prostate cancer. … READ MORE …